Autoimmunity Biosolutions

Autoimmunity BioSolutions is pioneering a genetically-targeted approach to treat refractory autoimmune diseases by neutralizing the soluble IL-7 receptor (sIL7R). The company's foundational hypothesis is that a common SNP (rs6897932) drives sIL7R overexpression, which is a key driver of pathogenesis and non-response in approximately 30-50% of patients with conditions like rheumatoid arthritis, lupus, and type 1 diabetes. ABS is developing a monoclonal antibody against sIL7R, aiming to 'reset' immune function without broad immunosuppression. This positions the company to address a significant unmet need in autoimmune care through a personalized medicine lens.

Monoclonal antibody platform targeting the soluble Interleukin-7 Receptor (sIL7R), a pathway driven by a genetic variant (SNP rs6897932) that enhances sIL7R expression and drives autoimmune pathology in refractory patients.

ABS operates in the highly competitive autoimmune therapeutics space, dominated by large pharma companies with broad immunosuppressants (e.g., TNF, IL-6, JAK inhibitors). Its direct competition is limited as targeting sIL7R is a novel approach, but it competes for funding, patient recruitment, and market share against all companies developing therapies for refractory RA, lupus, and T1D. Its key differentiator is its genetically-defined, precision medicine strategy.